Design of novel nanoformulation to decrease cardiotoxicity of doxorubicin

MLA

Ilić, Krunoslav, et al. Design of Novel Nanoformulation to Decrease Cardiotoxicity of Doxorubicin. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.57a035e5b1ae..e28d78417ca0f70a7794c513c3bb8e3c&authtype=sso&custid=ns315887.

APA

Ilić, K., Drinković, N., Debeljak, Ž., Micek, V., Kalčec, N., Pavičić, I., Tűreli, E., Gűnday Tűreli, N., & Vinković Vrček, I. (2022). Design of novel nanoformulation to decrease cardiotoxicity of doxorubicin.

Chicago

Ilić, Krunoslav, Nikša Drinković, Željko Debeljak, Vedran Micek, Nikolina Kalčec, Ivan Pavičić, Emre Tűreli, Nazende Gűnday Tűreli, and Ivana Vinković Vrček. 2022. “Design of Novel Nanoformulation to Decrease Cardiotoxicity of Doxorubicin,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.57a035e5b1ae..e28d78417ca0f70a7794c513c3bb8e3c&authtype=sso&custid=ns315887.